This study investigated the association between gingival hyperplasia and various systemic diseases and medications. Data from 1055 patients were analyzed, including those with leukemia, pregnancy, diabetes, and those taking medications known to induce gingival hyperplasia (phenytoin, cyclosporine, calcium channel blockers). Results indicated a significantly higher prevalence of gingival hyperplasia in patients with leukemia (40%, 95% CI: 30-50%) and poorly controlled diabetes (25%, 95% CI: 20-30%) compared to the control group (4%, 95% CI: 2-6%). Pregnancy also showed a statistically significant increase in gingival hyperplasia, with prevalence rising from 15% in the first trimester to 25% in the third trimester. Drug-induced gingival hyperplasia was observed in a substantial proportion of patients receiving phenytoin (35%), cyclosporine (25%), and calcium channel blockers (27%). Clinical characteristics of gingival hyperplasia varied depending on the underlying etiology, with leukemia-associated hyperplasia often presenting as severe, generalized, and friable tissue. These findings highlight the importance of considering systemic factors and medication profiles when assessing and managing gingival hyperplasia. Further research is needed to elucidate the mechanisms underlying these associations and to optimize treatment strategies.

ZENODO DOI: - https://doi.org/10.5281/zenodo.13968663

This study investigates the prevalence, causes, and consequences of occupational lifestyle disorders among bank clerical employees in Hyderabad, Telangana. With the rapid growth of the banking sector and increasing demands placed on clerical staff, there is a pressing need to understand how occupational factors contribute to health issues in this demographic. A mixed-methods approach was employed, incorporating quantitative surveys to assess the prevalence of lifestyle disorders, such as musculoskeletal disorders, stress, obesity, and metabolic syndromes, alongside qualitative interviews to explore the underlying causes and personal experiences of affected employees.

Findings reveal a significant prevalence of lifestyle disorders among bank clerical staff, with stress and musculoskeletal complaints being the most reported issues. Contributing factors identified include prolonged sedentary behavior, high workload, inadequate ergonomic practices, and limited physical activity. The study also highlights the consequences of these disorders on employee well-being, job satisfaction, and overall productivity.

The results underscore the urgent need for targeted interventions, including ergonomic training, stress management programs, and promoting a culture of health and wellness within the workplace. By addressing these lifestyle disorders, banks can enhance employee well-being, reduce healthcare costs, and improve overall organizational performance. This research provides valuable insights for policymakers, human resource managers, and health professionals aiming to mitigate occupational health risks in the banking sector.

This manuscript presents comprehensive treatment for children suffering from functional anemia with chronic kidney disease and evaluates their hemodynamic parameters and cytokine profile. The results of iron metabolism indicators (serum iron, serum ferritin, and transferrin), hemoregulatory hormones (erythropoietin and hepcidin), and pro-inflammatory blood markers (IL-6 and TNF-α) are determined. The therapy method included sucrosomal iron (Sideral) + erythropoietin (Repo) alongside traditional therapy. Thus, an individual approach is necessary for treating functional anemia in patients with varying degrees of chronic kidney disease.

Lung adenocarcinoma (LUAD), the most common histological subtype of lung cancer, is a highly heterogeneous disease with significant variability in clinical outcomes and responses to treatment. Traditional classifications based on histopathological characteristics have proven insufficient for personalized therapy due to the complexity of molecular alterations within tumors. As precision medicine gains prominence, molecular stratification based on gene expression profiling has emerged as a powerful approach to better classify lung adenocarcinoma, enabling more targeted and effective therapeutic strategies.

Gene expression profiling allows for the identification of specific molecular signatures and genetic alterations that drive the progression and behavior of lung adenocarcinoma. Through high-throughput technologies such as RNA sequencing (RNA-seq) and microarray analysis, large-scale data on gene expression patterns can be generated, providing insights into the biological mechanisms underlying tumor heterogeneity. This molecular information enables stratification of LUAD into distinct subgroups with unique molecular profiles, each associated with specific clinical characteristics, prognosis, and therapeutic sensitivities. Understanding these molecular differences not only improves diagnostic accuracy but also offers the potential to identify novel therapeutic targets and biomarkers for patient selection.

Several molecular subtypes of lung adenocarcinoma have been identified through gene expression profiling, each characterized by distinct genomic alterations and signaling pathway dysregulations. One well-recognized subtype is driven by alterations in the epidermal growth factor receptor (EGFR) gene, which is found in a significant proportion of LUAD patients. EGFR mutations are particularly prevalent in non-smoking populations and are associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs), making them critical for treatment stratification. Similarly, other subtypes harbor mutations in genes such as KRAS, BRAF, and ALK, each of which has unique therapeutic implications.

In addition to driver mutations, gene expression profiling has identified several immune-related subtypes of lung adenocarcinoma, which differ in their tumor immune microenvironments and responses to immune checkpoint inhibitors (ICIs). Tumors with high expression of immune-related genes, often referred to as "hot" tumors, are characterized by active immune infiltration and are more likely to respond favorably to immunotherapy. Conversely, "cold" tumors, with low immune infiltration, may require combination therapies to enhance immune responsiveness.

A more comprehensive understanding of these subtypes through molecular stratification has significant implications for improving treatment outcomes. For instance, patients with EGFR-mutant or ALK-rearranged tumors benefit greatly from targeted therapies, which can lead to improved progression-free survival. Similarly, immune-related subtypes can guide the use of immunotherapy, ensuring that only patients most likely to benefit from these treatments receive them, while sparing others from potential toxicity and side effects.